GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Enterprise Value

Pharos IBio Co (XKRX:388870) Enterprise Value : ₩74,113.46 Mil (As of May. 15, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pharos IBio Co's Enterprise Value is ₩74,113.46 Mil. Pharos IBio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-10,554.16 Mil. Therefore, Pharos IBio Co's EV-to-EBIT ratio for today is -7.02.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Pharos IBio Co's Enterprise Value is ₩74,113.46 Mil. Pharos IBio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-9,751.26 Mil. Therefore, Pharos IBio Co's EV-to-EBITDA ratio for today is -7.60.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Pharos IBio Co's Enterprise Value is ₩74,113.46 Mil. Pharos IBio Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was ₩0.00 Mil. Therefore, Pharos IBio Co's EV-to-Revenue ratio for today is .

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Pharos IBio Co's Enterprise Value is ₩74,113.46 Mil. Pharos IBio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-10,345.57 Mil. Therefore, Pharos IBio Co's EV-to-FCF ratio for today is -7.16.


Pharos IBio Co Enterprise Value Historical Data

The historical data trend for Pharos IBio Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Enterprise Value Chart

Pharos IBio Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial - - - 166,406.96 82,252.70

Pharos IBio Co Quarterly Data
Dec19 Dec20 Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166,406.96 219,856.12 119,565.56 96,631.41 82,252.70

Competitive Comparison of Pharos IBio Co's Enterprise Value

For the Biotechnology subindustry, Pharos IBio Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharos IBio Co's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharos IBio Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Pharos IBio Co's Enterprise Value falls into.


;
;

Pharos IBio Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Pharos IBio Co's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

Pharos IBio Co's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharos IBio Co  (XKRX:388870) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Pharos IBio Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=74113.462/-10554.164
=-7.02

Pharos IBio Co's current Enterprise Value is ₩74,113.46 Mil.
Pharos IBio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-10,554.16 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Pharos IBio Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=74113.462/-9751.255
=-7.60

Pharos IBio Co's current Enterprise Value is ₩74,113.46 Mil.
Pharos IBio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-9,751.26 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Pharos IBio Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=74113.462/0
=

Pharos IBio Co's current Enterprise Value is ₩74,113.46 Mil.
Pharos IBio Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0.00 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Pharos IBio Co's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=74113.462/-10345.566
=-7.16

Pharos IBio Co's current Enterprise Value is ₩74,113.46 Mil.
Pharos IBio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-10,345.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharos IBio Co Enterprise Value Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharos IBio Co Business Description

Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines